Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 (Cadonilimab) +/- Lenvatinib in Advanced HCC
NCT04728321Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate up to 2 years. Started Jan 2021; status: completed.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04728321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728321.